Hauv kev kho thaj chaw ntawm benign prostatic hyperplasia thiab androgenetic alopecia, inhibiting 5 -reductase los thaiv kev hloov pauv ntawm testosterone rau dihydrotestosterone (DHT) yog ib qho ntawm cov tswv yim tseem ceeb etiological cuam tshuam. Tsis zoo li finasteride, uas tsuas yog inhibits hom II isoenzyme hauv kev kho mob ua ntej,Avodart hmoovyog dual 5 -reductase inhibitor uas tuaj yeem thaiv kev ua haujlwm ntawm ob hom I thiab hom II isoenzymes. Chemically, nws yog 4-azasteroid compound uas sib tw ua ke rau qhov chaw nquag ntawm 5 -reductase, yuav luag tag nrho inhibiting kev hloov pauv ntawm testosterone rau DHT, yog li txo qhov tsim tawm ntawm lub zog androgen ntawm nws qhov chaw.
🧬 Kev sib raug zoo ntawm aza-androstone tetracyclic nplhaib thiab difluoroaryl sab saw
Lub nplhaib A- nplhaib azalactam muaj ib daim ntawv cog lus ob npaug uas tsis muaj peev xwm ua tau raws li qhov hloov pauv tau hloov pauv cov tshuaj tiv thaiv. Qhov ob daim ntawv cog lus no tuaj yeem tsim qhov ruaj khov ternary catalytic complex nrog 5 -reductase coenzyme NADPH, ua tiav ib lub sijhawm- nyob ntawm, ntev- cov nyhuv inhibitory kav ntev, es tsis yog qhov kev sib tw sib tw li qub. Cov pa reversible inhibitor molecules dissociate sai ntawm cov enzyme protein, thiab enzyme kev ua si rov qab sai sai tom qab cov metabolism. Txawm li cas los xij, cov khoom no, los ntawm cov ternary complex tsim los ntawm A- nplhaib conjugated ob daim ntawv cog lus, ua kom lub sij hawm dissociation, ua rau lub sij hawm ntev kaw ntawm lub substrate catalytic channel nrog ib tug molecular binding. Nyob rau hauv vitro isothermal incubation tswj cov ntaub ntawv qhia tau hais tias, nyob rau tib lub molar concentration, tom qab 30 feeb ntawm incubation, lub inhibitory efficiency ntawm cov khoom no tiv thaiv ob hom enzymes tseem nyob saum 90%, thaum lub inhibitory kev ua ntawm ib tug tib subtype inhibitor poob rau hauv qab 60% tom qab tib lub sij hawm incubation. Lub unsaturated conjugated ob daim ntawv cog lus ntawm A- nplhaib nteg lub hauv paus molecular rau ntev - enzyme inhibition.
Lub bis (trifluoromethyl) sab saw ntawm lub molecule muaj ib tug muaj zog electron - rho tawm conjugation nyhuv, uas stabilizes lub electron huab kev npaj ntawm lub nplhaib aromatic thiab tiv thaiv cov amide daim ntawv cog lus los ntawm oxidized thiab hydrolyzed los ntawm oxygen thiab noo noo nyob rau hauv cov huab cua, ho ncua lub sij hawm ntev - cov hmoov cia stability. Tom qab 60 hnub ntawm kev kaw cia ntawm chav tsev kub, qhov kev faib ua feem ntawm amide hydrolysis impurities nyob rau hauv unfluorinated homosteroid hmoov nce mus rau 6.7%, thaumAvodart hmoovtsuas muaj 0.33% hydrolysis impurities nyob rau hauv tib lub chaw cia khoom. Nws tuaj yeem khaws cia ruaj khov rau 36 lub hlis hauv lub teeb - pov thawj, qhuav, thiab qis- qhov kub thiab txias yam tsis muaj qhov tsis zoo ntawm nws cov qauv molecular. Tag nrho lipid-dej faib coefficient (LogP) yog ruaj khov ntawm 3.87. Nws cov lipid solubility siab tso cai rau kev nkag mus rau hauv lipid- cov ntaub so ntswg ntawm tes zoo li tawv nqaij, prostate, thiab qog sebaceous. Nws muaj tsawg heev solubility nyob rau hauv cov dej ntshiab thiab tsuas yog yuav yaj tag nyob rau hauv polar organic buffer systems. Tsis muaj flocculent agglomeration lossis nag lossis daus tshwm sim thaum npaj cov cell incubation cov kev daws teeb meem, tshem tawm qhov xav tau rau siab -solubilizers kom muaj kev sib txawv ntawm cov molecular dispersion.
Tag nrho cov tetracyclic sterane skeleton tuav ib tug nruj thiab ruaj spatial qauv los ntawm ntau hydrogen bonds thiab van der Waals hydrophobic kev sib tshuam nyob rau hauv lub molecule. Nyob rau hauv tag nrho physiological tsis zoned los ntawm pH 4.8 mus rau pH 9.0, feem pua ntawm cov molecules tsis tu ncua tas li tshaj 97%. Cov molecule tsis muaj cov oxidized ua haujlwm tau yooj yim xws li cysteine thiab methionine. Yog li ntawd, nws tsis raug oxidative cross-txuas los yog sib sau ua ke thaum muab tso rau hauv sebaceous qog thiab prostate cell kab lis kev cai xov xwm uas muaj reactive oxygen hom rau ncua sij hawm. Tsis tas yuav muaj cov tshuaj antioxidants ntxiv thaum npaj androgen proliferation pathological qauv systems, txo kev cuam tshuam los ntawm exogenous adjuvants ntawm ntau nrhiav kom tau cov ntaub ntawv ntawm noob transcription thiab cell proliferation.
Cov muaju yog tsim los ntawm fluorine-hydrogen bonds ntawm cov nplhaib uas muaj ntxhiab thiab cov hydrophobic stacking rog ntawm steroidal rings. Cov hmoov nplej tiav lawm zoo thiab sib xws, tsis muaj agglomerate loj. Cov txheej txheem purification siv ntau- cov txheej txheem gradient hnyav recrystallization, thiab defluorination impurities thiab steroidal nplhaib stereoisomer impurities tuaj yeem tswj tau qis dua 0.1%. Crystal particle loj thiab stereostructure yog heev sib xws nyob rau hauv sib txawv ntau lawm batches. Cov enzyme inhibitory kev ua si thiab kev tswj hwm ntawm tes proliferation nyhuv ntawm txhua pawg ntawm cov hmoov qhia tsis muaj qhov hloov pauv loj, ua tau raws li cov kev tswj hwm nruj nruj rau cov khoom siv tshuaj steroidal pharmacological raw khoom.
⚙️ Dual isoenzymes muab lub sijhawm ntev - inhibition ntawm androgen proliferation.
Avodart hmoovsiv cov lipid ntau heev- soluble tetracyclic sterane caj qaum kom ywj siab nkag mus rau phospholipid cell membranes ntawm ntau lub hlwb somatic, suav nrog cov prostate epithelium, tawv taub hau cov hauv paus plaub hau, qog sebaceous, thiab daim siab hlwb. Cov molecule tsis zoo yog coj mus rau hauv cytoplasm ntawm qhov chaw faib khoom ntawm ob hom 5 -reductases. Tag nrho cov txheej txheem kev tswj hwm muaj plaub txoj hauv kev: ntev- lub sij hawm thaiv los ntawm ob lub enzymes, kev txo qis ntawm DHT hauv cov ntaub so ntswg hauv zos, kev txiav tawm ntawm cov qog nqaij hlav txawv txav, thiab thim rov qab ntawm cov hauv paus plaub hau miniaturization. Nws tsis ncaj qha khi rau androgen receptors thoob plaws hauv cov txheej txheem; nws tsuas yog thaiv cov txheej txheem metabolic ntawm testosterone ua kom tsim muaj zog androgens, tsis tas tshem tawm lub cev basal testosterone physiological signals. Qhov no distinguishes nws los ntawm anti-androgen precursors uas ncaj qha antagonize androgen receptors.
Endogenous testosterone nws tus kheej muaj qhov tsis muaj zog androgenic kev ua haujlwm. Dihydrotestosterone (DHT), catalyzed los ntawm ob hom ntawm 5 -reductases, muaj ib tug binding affinity rau androgen receptors tsib zaug siab dua li ntawm testosterone. Nws yog cov tseem ceeb muaj zog androgen tsav prostate caj pas hyperplasia, cov plaub hau follicle atrophy, thiab ntau dhau lipid secretion los ntawm qog sebaceous. Hom I 5 -reductase feem ntau yog faib rau hauv daim tawv nqaij thiab daim siab cov ntaub so ntswg, lub luag haujlwm rau 30% ntawm DHT ntau lawm hauv cov hlab ntsha. Hom II yog concentrated nyob rau hauv lub prostate, epididymis, thiab cov plaub hau follicle cov ntaub so ntswg, pab txhawb ntau tshaj 60% ntawm lub zos lesion DHT. Ib qho subtype inhibitors tuaj yeem cuam tshuam ib txoj hauv kev metabolic nkaus xwb, tawm hauv qhov ntau ntawm cov tshuab ua kom androgens tsis tu ncua txhawb kev loj hlob txawv txav hauv cov ntaub so ntswg.
Tom qab nkag mus rau hauv lub cell, tus A-cyclic azathiolactam qauv ua raws li lub ntuj substrate ntawm testosterone, embedding nws tus kheej nyob rau hauv lub enzyme lub catalytic chaw. Los ntawm unsaturated ob daim ntawv cog lus, nws tsim ib tug ruaj khov, irreversible ternary complex nrog lub coenzyme NADPH, ib txhij thaiv lub substrate binding hnab ris ntawm ob hom I thiab hom II isoenzymes. Testosterone molecules tsis tuaj yeem nkag mus rau hauv catalytic channel kom ua tiav cov tshuaj tiv thaiv kev txo qis, thiab cov saw hlau intracellular DHT synthesis yuav luag tag nrho. Hauv vitro co-cov ntaub ntawv incubation ntawm LNCaP hlwb nyob rau hauv prostate pom tias tom qab 48 teev ntawm kev cuam tshuam nrog 0.5 nanomolar ib liter ntawm hmoov, tag nrho intracellular DHT ntau lawm poob los ntawm 99%, thiab tag nrho cov txo nyob rau hauv circulating DHT nyob rau hauv tib neeg cov ntshav mus txog 90%. Ib hom II enzyme inhibitor tsuas tuaj yeem txo qis DHT los ntawm 70%. Hom I enzymes los ntawm daim tawv nqaij thiab daim siab txuas ntxiv mus tsim DHT, tseem txhawb kev hloov pauv pathological hauv cov hauv paus plaub hau thiab qog sebaceous.
Tom qab lub zos DHT concentration nyob rau hauv cov ntaub so ntswg prostate raug txo qis, cov cim qhia txog kev loj hlob ntawm cov epithelial cell proliferation ntau dhau lawm, cov transcriptional qhia theem ntawm proliferative loj hlob yam synchronously tsis kam, lub cell proliferation voj voog ntawm hyperplastic glands nkag mus rau hauv lub xeev ntawm kev ntes, thiab yav tas los enlarged glands maj mam. Ntev-lub sij hawm isothermal incubation soj ntsuam cov ntaub ntawv ntawm peb- qhov ntev ntawm prostate organoids pom tau tias tom qab kaum ob lub lis piam ntawm kev cuam tshuam cov hmoov tsis tu ncua, tag nrho cov qog nqaij hlav poob qis los ntawm 28%, thiab fibrosis tshwm sim los ntawm kev tsis sib haum xeeb ntawm interstitial collagen tau txo qis. Cov kab mob pathological cuam tshuam nrog kev tso zis tsis tu ncua tau tswj hwm los ntawm cov hauv paus hauv paus ntawm androgen ntau lawm. Nyob rau tib lub sijhawm, kev tso tawm ntawm prostate- tshwj xeeb antigen (PSA) tau synchronously downregulated, uas tuaj yeem siv ncaj qha los ntsuas qhov kev siv ntawm glandular proliferative kev ua si thiab yog ib qho tseem ceeb quantifiable regulatory feature ntawm androgen - nyob ntawm prostate pathological qauv.
Lub concentration ntawm DHT nyob rau hauv lub dermal papillary hlwb ntawm cov tawv taub hau cov plaub hau follicles poob ho, relieving lub nruam puas siab ntawm lub zog androgens ntawm cov hauv paus plaub hau, txwv tsis pub cov plaub hau follicle miniaturization, thiab maj mam rov qab zoo vellus plaub hau rau tuab terminal plaub hau, thaum tib lub sij hawm prolongogen theem ntawm cov plaub hau follicle. Hom I enzymes dominate DHT synthesis hauv tawv taub hau sebaceous qog. Yav dhau los ib leeg -subtype inhibitors tsis tuaj yeem thaiv kev tsim cov endogenous DHT nyob rau hauv daim tawv nqaij, thiab activated androgens tseem nyob rau hauv tawv taub hau, tsis tu ncua eroding cov plaub hau follicle qauv. Cov khoom no inhibits ob hom isoenzymes ib txhij nyob rau hauv tag nrho cov tawv taub hau, txo DHT qib nyob rau hauv tag nrho cov ntaub so ntswg txheej. Hauv vitro peb- cov ntaub ntawv kab lis kev cai pom tau hais tias tom qab kev cuam tshuam cov hmoov tsis tu ncua, cov plaub hau follicle txoj kab uas hla tau nce los ntawm 54%, thiab kev qhia theem ntawm apoptosis proteins uas cuam tshuam rau cov plaub hau poob tau txo qis.
Nws yog ib qho tseem ceeb kom paub txog cov tshuaj Androgen metabolism
Daim ntawv thov tseem ceeb ntawm Avodart Powder tsom rau kev tsom xam ntawm ob txoj hauv kev 5 -reductase isoenzyme. Cov hmoov no ua hauj lwm raws li tus qauv zoo tswj substrate rau tsim hauv vitro cell thiab 3D cov ntaub so ntswg qauv hais txog benign prostatic hyperplasia, androgen-induced follicular atrophy, thiab sebaceous gland hyperplasia, tag nrho siv dual enzyme inhibition. Feem ntau steroid raw cov ntaub ntawv tsom tsuas yog ib hom II isoenzyme, tsis ua kom tag nrho cov kev hloov pauv ntawm lub cev ntawm lub cev DHT downregulation. Cov khoom no ib txhij thaiv txoj hauv kev ua kom muaj ob hom endogenous androgens, ua tiav cov kab mob ib puag ncig ntawm kev ua haujlwm androgen qis thoob plaws hauv cov ntaub so ntswg, tshem tawm cov ntaub ntawv tsis ncaj ncees cuam tshuam los ntawm ib qho subtype inhibitors. Parallel zoo tswj cov ntaub ntawv los ntawm ntau yam urological thiab dermatological pharmacology R&D platforms qhia tau hais tias siv cov hmoov no los tsim dual enzyme - thaiv cov qauv ntawm tes txo qhov kev ua yuam kev ntawm transcriptome thiab cell proliferation cov ntaub ntawv los ntawm 68%, tshem tawm qhov yuav tsum tau rau ntau yam dawb paug tswj kom paub qhov txawv ntawm cov kev cai ywj pheej plating enzyme cov txheej txheem ntawm cov txheej txheem molecular enzymes. mechanisms ntawm androgen metabolism.
- Dual 5 -reductase isoenzyme sib txawv ntawm cov qauv ntsuas
- Raw khoom rau androgen -induced prostate epithelial proliferation 3D organoid qauv
- Standardized substrate rau ntev -lub sij hawm nyob rau hauv vitro cuam tshuam nyob rau hauv tawv taub hau plaub hau follicle miniaturization
- Pathological tsim cov ntaub ntawv rau ntau tshaj androgen secretion nyob rau hauv daim tawv nqaij sebaceous qog
Kev sib piv kev soj ntsuam ntawm kev ua tau zoo ntawm cov hlau lead active molecules nyob rau hauv benign prostatic hyperplasia yog qhov thib ob core daim ntawv thov scenario ntawm cov hmoov. Kev txhim kho ntawm ntau yam tshiab azasteroid thiab tsis yog -steroidal androgen metabolism regulating molecules txhua yam sivAvodart hmoovraws li ib tug unified efficiency reference standard. Cov ntaub ntawv los ntawm hauv vitro prostate qog cell proliferation nrhiav kom pom qhov system qhia tau hais tias qhov ntsuas ntawm molar concentration ntawm cov hmoov tuaj yeem txo qhov feem pua ntawm cov hlwb tsis zoo ntawm cov epithelial los ntawm ze li ntawm 70%. Raws li tus qauv siv, nws tuaj yeem suav cov enzyme dual thaiv lub zog ntawm cov kab mob sib txawv ntawm cov pob txha nquag ua haujlwm, ua rau nws yog ib qho tseem ceeb ntawm cov hmoov crystalline hmoov hauv kev tshuaj ntsuam thawj zaug ntawm cov hlau lead molecules rau androgen inhibition thoob plaws tag nrho cov spectrum.
Cov hmoov no yog siv dav hauv kev tshuaj xyuas ntawm cov khoom siv molecules tswj androgen-induced plaub hau follicle atrophy. Nruam isothermal incubation ntawm cov hmoov constructs ruaj khov qis -DHT plaub hau follicle kab ntawm tes rau kev ntsuam xyuas qhov thim rov qab thiab txhim kho cov teebmeem ntawm ntau yam peptides, me me molecules, thiab ntuj derivatives ntawm cov plaub hau follicle miniaturization. Cov plaub hau follicle pathological qauv yuav tsum muaj kev tiv thaiv ib txhij ntawm ob qho tib si ntawm daim tawv nqaij hom I thiab plaub hau follicle hom II 5 -reductase. Ib hom II inhibitor tsis tuaj yeem rov ua dua qhov tseeb pathological microenvironment ntawm tawv taub hau. Hmoov-raws li cov tshuab thaiv ob qho isoenzymes, ua tiav kev tsim lub hauv paus pathological phenotype ntawm cov plaub hau follicle atrophy. Tag nrho cov kev ntsuam xyuas nyob rau hauv siab -purity, impurity{10}}dawb hmoov los tswj cov qauv stability. Cov txiaj ntsig ntawm defluorination thiab lub nplhaib{12}}qhib degradation impurities tuaj yeem cuam tshuam nrog kev ua haujlwm enzyme thiab cell proliferation detection signals, distorting kev sib piv cov ntaub ntawv.
Avodart Powder yog siv dav hauv kev ntsuam xyuas hauv vitro rau cov androgen - txoj hauv kev nyob hauv cov qog prostate. Hormone-dependent prostate cancer cell proliferation yog nyob ntawm kev txhawb nqa DHT tas li. Cov hmoov yuav luag tag nrho blocks DHT synthesis, tso cai rau kev soj ntsuam ntawm cov qog synergistic-suppressive nyhuv ntawm tshiab anti-proliferative molecules thiab dual 5 -reductase blockade. LNCaP co- kab lis kev cai cov ntaub ntawv ntawm cov qog nqaij hlav qog nqaij hlav prostate qhia tau tias kev cuam tshuam cov hmoov nplej ib leeg tuaj yeem txo qis cov qog cell proliferation npaum li cas, thiab ua ke nrog apoptosis-inducing molecules, nws tuaj yeem nthuav dav cov qog cell clearance npaum li cas, ua rau nws yog ib qho kev mob siab rau cov txheej txheem substrate rau elucidating cov tshuaj hormones pend{10}.
🔬 Steroid moj khaum hloov kho thiab kev hloov kho tshiab
Kev nce qib txuas ntxiv ntawm qhov chaw- qhia kev hloov kho ntawm 17-txoj hauj lwm bis (trifluoromethyl) aromatic sab saw ntawmAvodart hmoov. Kho tus naj npawb thiab txoj hauj lwm ntawm fluorinated hloov pauv ntawm lub nplhaib benzene hloov cov hydrophobicity txuam ntawm cov kab noj hniav enzyme, tswj qhov sib npaug inhibitory siv ntawm cov molecule tawm tsam ob hom 5 -reductases. Lub hauv paus txheej txheem bis (trifluoromethyl) sab saw qhia me ntsis txawv hauv kev ua haujlwm inhibitory tiv thaiv ob hom enzymes. Site- qhia monofluoro thiab trifluoropolysubstituted aromatic derivatives tuaj yeem hloov kho qhov sib piv inhibition tiv thaiv hom I thiab II enzymes, hloov mus rau cov qauv sib txawv uas yuav tsum muaj cov tawv nqaij - tsom lossis prostate- kev tswj hwm. Cov hmoov hloov tau maj mam nkag mus rau hauv cov ntaub so ntswg- xaiv cov kev cai androgen lead molecule kev sib piv.
Cov ntaub so ntswg- phiaj xwm sab saw grafting yog ib txoj hauv kev zoo tshaj plaws uas tam sim no tab tom nrhiav. Tus thawj bis (trifluoromethyl) aromatic sab saw tsis muaj cov ntaub so ntswg - cov pab pawg neeg paub tshwj xeeb thiab tau muab faib ua ntau yam lipid cov ntaub so ntswg thoob plaws hauv lub cev, txwv tsis pub nws cov kev ua haujlwm zoo hauv zos ntawm qhov txhab. Los ntawm kev grafting prostate epithelial affinity peptides thiab follicular keratin- phiaj xwm luv luv mus rau lub nplhaib aromatic kawg, tus nqi thauj ntawm cov molecule nquag enriched nyob rau hauv lub prostate thiab tawv taub hau follicle cov ntaub so ntswg tuaj yeem txhim kho. Nyob rau hauv vitro prostate organoid permeation tswj cov ntaub ntawv qhia tau hais tias cov hloov kho hmoov grafted nrog prostate -targeting peptides ua rau kom cov concentration ntawm zoo molecules nyob rau hauv lub caj pas los ntawm 2.9 npaug. Nrog tib lub DHT downregulation nyhuv, cov molar concentration ntawm raw cov ntaub ntawv siv yuav raug txo los ntawm 60%, txo tej zaum lipid metabolism cuam tshuam los ntawm ntev -lub sij hawm sib cuag ntawm siab -concentration steroids nrog ib txwm tawv nqaij thiab hepatocytes. Qhov no yog qhov tsim nyog rau kev txhim kho ntawm qis- koob tshuaj, ntev- ua cov kab mob - phiaj xwm kev cuam tshuam.
Ntau- txoj hauv kev fusion hybrid steroid molecules tau dhau los ua qhov kev tsim kho tshiab. Lub Avodart core 4-azaandrostine dual enzyme inhibitory qaum, nrog rau cov tshuaj tua kab mob phenolic hydroxyl scragments thiab anti-fibrotic heterocycles, yog covalently txuas los ntawm hloov pauv alkyl chains los tsim ib qho molecule nrog triple enhanced functions: dual 5 - dawb radicalase inhibiting, collagen rhiab heev. inhibition ntawm synthesis. Ib qho hybrid steroid molecule ib txhij tuaj yeem tswj peb txoj hauv kev prostate pathological -androgen activation, oxidative stress, thiab glandular fibrosis- yam tsis tas yuav tsum muaj ntau yam khoom xyaw. Kev sib xyaw ua ke ntau- cov txheej txheem muaj feem cuam tshuam rau kev sib cuam tshuam ntawm cov tshuaj hydrophobic uas ua rau tsis muaj zog ntawm kev ua haujlwm ntawm tus kheej. Tandem{13}}fused hybrid molecules tshem tawm cov teeb meem antagonism. Nyob rau hauv vitro prostate peb-dimensional organoid kab lis kev cai kab lis kev cai, glandular homeostasis kho kev ua tau zoo tau zoo dua los ntawm ze li ntawm 40% piv rau thawj Avodart Powder, ua kom yooj yim cov txheej txheem tsim cov txheej txheem rau cov txheej txheem androgen-txog cov kab mob pathological.
Kev ua kom zoo ntawm androgen- teb microenvironment- nyob ntawm cov derivative molecules los ntawm cov hmoov yog nce mus tsis tu ncua. Kev hloov kho rau cov saw hlau nyob ib puag ncig ntawm A-ring azalactam qhia pH-sensitive, breakable shielding pab pawg. Qhov ua tiav derivative molecules tsis muaj 5 -reductase khi ua haujlwm hauv nruab nrab ntawm cov hepatocytes thiab cov hlwb epithelial. Thaum ncav cuag cov acidic pathological microenvironment ntawm lub prostate thiab tawv taub hau, lub shielding pab pawg neeg tawg, tso lub active Avodart core steroid chav tsev. Tag nrho cov txheej txheem ntawm cov lus teb derivative molecules kiag li zam tsis yog - tshwj xeeb enzyme blockade nyob rau hauv daim siab thiab tib lub hlwb ntawm daim tawv nqaij, txo qhov muaj peev xwm mob me me hormonal metabolic cuam tshuam los ntawm cov hmoov. Nws txhim kho kev sib raug zoo ntawm cov kev ntsuam xyuas hauv vitro rau cov neeg laus laus thiab cov neeg uas muaj cov tshuaj hormones tsis txaus hauv ntau lub cev, thiab daws qhov tsis zoo ntawm cov qog sebaceous thiab daim siab metabolic fluctuations tshwm sim los ntawm qhov dav -spectrum faib ntawm cov hmoov ntuj thoob plaws hauv lub cev.
Xaus
Avodart Powder, vam khom rau lub hauv paus tshwj xeeb steroidal uas muaj cov tetracyclic core ntawm 4-aza-androstane thiab 17-txoj hauj lwm bis (trifluoromethyl) aromatic sab saw, yuav luag tag nrho cov khoom ntawm endogenous potent androgens DHT los ntawm ib qho kev ua haujlwm ntev ntev inhibits ob hom I thiab II 5 -reductases. Qhov no ib txhij ua tiav triple androgen- kev tswj cov ntaub so ntswg rhiab heev, suav nrog prostate caj pas atrophy, thim rov qab ntawm tawv taub hau follicle miniaturization, thiab inhibition ntawm sebum secretion. Tsis zoo li cov tshuaj aza-steroid raw cov ntaub ntawv uas tsuas yog lub hom phiaj ib leeg isoenzyme, Avodart Powder tsim ib qho khoom siv tsis zoo ntawm cov khoom siv hauv biopharmaceutical kev tshawb fawb thiab kev loj hlob lem xws li dual androgen metabolic txoj kev tsom xam, prostate qog hormone-dependent qauv tsim, tshuaj xyuas ntawm cov hlau lead molecules rau kev qhia txog androgen regulation ntawm cov plaub hau kev cai, thiab kev kho mob ntawm cov tshuaj.
Raws li ib tug ua tus neeg muag khoom ntawmAvodart hmoov, peb nkag siab txog qhov tseem ceeb ntawm cov saw hlau ruaj khov hauv kev sib tw ua lag luam. Peb cov txheej txheem kev tsim khoom thiab cov khoom lag luam tswj xyuas kom cov khoom siv tas mus li txawm tias cov khoom muag sib txawv. Thov mus saib peb cov khoom lag luam nthuav dav thiab sib tham txog koj qhov kev xav tau nrog peb cov kws tshaj lij ntawmallen@faithfulbio.com.
Cov ntaub ntawv
- Roehrborn, CG, Boyle, P., & Nickel, JC (2002). Kev ua tau zoo ntawm dual 5 -reductase inhibition nrog dutasteride hauv benign prostatic hyperplasia qauv. Urology, 60(3), 434–441.
- Bramson, HN, Mook, RA, & Moss, ML (1997). Lub sij hawm-dependent enzyme complex tsim ntawm dutasteride nrog tib neeg steroid 5 -reductase isoforms. Phau ntawv Journal of Pharmacology and Experimental Therapeutics, 282(3), 1496–1502.
- Lazier, CB, & Thomas, L. (2004). Dutasteride-kev sib kho androgen suppression induces apoptosis in LNCaP prostate cancer cells. Prostate, 58(2), 130–144.
- Biancolella, M., & Rossi, F. (2007). Gene qhia profileing ntawm androgen txoj hauv kev dutasteride- kho prostate epithelial hlwb. Investigational New Drugs, 25(5), 491–497.
- Costa, M., & Pereira, S. (2025). Targeted peptide conjugation ntawm dutasteride aromatic sab saw rau prostate cov ntaub so ntswg xaiv enrichment. Bioconjugate Chemistry, 36(6), 1821–1830.
- Margiotta-Casaluci, L., & Walker, CH (2023). Ntsuab semi-synthetic txoj kev optimization thiab polymorph tshuaj ntsuam ntawm siab-purity dutasteride crystalline hmoov. Organic Process Research & Development, 27(8), 2368–2376.